Immune-related cystitis and bladder tuberculosis induced by sintilimab
10.3760/cma.j.cn114015-20231117-00816
- VernacularTitle:信迪利单抗致免疫相关性膀胱炎和膀胱结核
- Author:
Bing WANG
1
;
Quan WANG
1
;
Xiaojing SUI
1
;
Jinfeng LI
1
;
Yingjie CUI
1
;
Yuan ZHANG
1
Author Information
1. 山东大学附属威海市立医院药剂科，威海 264200
- Publication Type:Journal Article
- Keywords:
Cystitis;
Tuberculosis, urogenital;
Immune checkpoint inhibitors;
Sintilimab;
Immune-related adverse effects
- From:
Adverse Drug Reactions Journal
2024;26(10):636-638
- CountryChina
- Language:Chinese
-
Abstract:
A 67-year-old male patient with esophageal cancer received sintilimab and chemotherapy [sintilimab injection 200 mg by IV infusion, 1 day before chemotherapy, paclitaxel (albumin bound) 200 mg by IV infusion on day 1 and 300 mg on day 5, and nedaplatin 80 mg by IV infusion on day 1 and 70 mg on day 2, 21 days as 1 cycle] for 4 cycles. Later, due to mediastinal lymph node metastasis, the patient received sintilimab and palliative radiotherapy one time. Eight days later, the patient developed urinary frequency, urgency and pain, urine routine showed 638 red blood cells/μl, and 2 141 white blood cells/μl. The T-cell test for mycobacterium tuberculosis infection was positive, and cystoscopy showed diffuse redness and swelling of bladder mucosa. The patient was diagnosed with immune-related cystitis and bladder tuberculosis, which was considered to be related to sintilimab. Methylprednisolone sodium succinate and anti-tuberculosis treatment were given. After 5 days of treatments, the patient′s aforementioned symptoms were improved and the urine routine returned to normal. Afterwards, sintilimab was not used again and relevant symptoms did not recur.
